US Market Report for Dental Growth Factor 2017 - MedCore
General Report Contents
Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
Market Drivers & Limiters for each chapter segment
Competitive Analysis for each chapter segment
Section on recent mergers & acquisitions
Most of the new products in this area are derived from advances made in the orthopedic field. However, adapting an orthopedic product for dental applications is not straightforward – a separate approval must be obtained from the U.S. Food and Drug Administration (FDA) for dental use. This has created a significant delay between when products are introduced to the orthopedic market and when they enter the dental market.
Dental growth factor products currently offered to the U.S. market in 2016 were GEM 21S®, INFUSE®, Osteocel® and Emdogain™. Over the forecast period, a number of additional growth factor combinations are expected to enter the tissue engineering product market. In 2005, the FDA approved the release of BioMimetic’s GEM 21S®, the first growth factor matrix approved for dental use. The product has since gained traction and received the CE mark approval to enter the European market in 2012.
In late 2006, Medtronic’s INFUSE®, a growth factor containing bone graft product, was also approved for dental use. Tissue engineering products are often employed in combination with bone graft substitutes. Certain products cater to a specific need; for that reason, the various growth factors in the market are not viewed as complete substitutes or directly in competition with one another.
Osteoinductivity refers to the ability of a graft to induce non-differentiated stem cells, or osteoprogenitor cells, to differentiate into osteoblasts, resulting in bone regeneration. However, only a few bone graft substitute materials have the capacity for osteoconductivity. Growth factors and other tissue engineering products enhance osteoconductivity, and are used to increase the rate and volume of bone regeneration.
Dental growth factor and tissue engineering products is a broad category that encompasses products used for facilitating and enhancing bone regeneration. This includes growth factors and enamel matrix protein solutions. Platelet rich plasma (PRP) is also used for these purposes, but will not be considered within this report.